Published online before print October 18, 2004, doi: 10.1161/01.CIR.0000146396.19081.73
(Circulation. 2004;110:2837-2842.)
© 2004 American Heart Association, Inc.
Coronary Heart Disease |
Ascorbic Acid Prevents Contrast-Mediated Nephropathy in Patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention
From the Department of Cardiology (K.S., E.A., S.K., P.I., A.M., V.V., G.P., D.K., D.V.C.), Onassis Cardiac Surgery Centre, Athens, Greece; the Biostatistics Unit and Nutrition Epidemiology Group (D.C.G.), University of Leeds, Leeds, UK; and the Division of Cardiology (C.E.B.), University of British Columbia, Vancouver, Canada.
Reprint requests to Dr K.S. Spargias, Onassis Cardiac Surgery Centre, 356 Syngrou Ave, 176 74, Athens, Greece. E-mail spargias{at}ocsc.gr
Received February 19, 2004; de novo received May 5, 2004; revision received June 30, 2004; accepted July 1, 2004.
Background— Contrast agents can cause a reduction in renal function that may be due to the generation of reactive oxygen species. Conflicting evidence suggests that administration of the antioxidant acetylcysteine prevents this renal impairment. The action of other antioxidant agents has not been investigated.
Methods and Results— We conducted a randomized, double-blind, placebo-controlled trial of ascorbic acid in 231 patients with a serum creatinine concentration 
1.2 mg/dL who underwent coronary angiography and/or intervention. Ascorbic acid, 3 g at least 2 hours before the procedure and 2 g in the night and the morning after the procedure, or placebo was administered orally. Contrast-mediated nephropathy was defined by an absolute increase of serum creatinine 0.5 mg/dL or a relative increase of 25% measured 2 to 5 days after the procedure. Contrast-mediated nephropathy occurred in 11 of the 118 patients (9%) in the ascorbic acid group and in 23 of the 113 patients (20%) in the placebo group (odds ratio [OR], 0.38; 95% confidence interval [CI], 0.17 to 0.85; P=0.02). The mean serum creatinine concentration increased significantly in the placebo group (from 1.36±0.50 to 1.50±0.54 mg/dL, P<0.001) and nonsignificantly in the ascorbic acid group (from 1.46±0.52 to 1.52±0.64 mg/dL, P=0.07). The mean increase in serum creatinine concentration was greater in the placebo group than in the ascorbic acid group (difference of 0.09 mg/dL; 95% CI, 0.00 to 0.17; P=0.049).
Conclusions— Prophylactic oral administration of ascorbic acid may protect against contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure.
Key Words: contrast media • kidney • angiography • angioplasty • antioxidants
Related Article:
Circulation 2004 110: 2773.
This article has been cited by other articles:
 |
|
 |
|
  G. Romano, C. Briguori, C. Quintavalle, C. Zanca, N. V. Rivera, A. Colombo, and G. Condorelli Contrast agents and renal cell apoptosis Eur. Heart J., May 8, 2008; (2008) ehn197v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. McCullough Contrast-Induced Acute Kidney Injury J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1419 - 1428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Toprak, M. Cirit, M. Tanrisev, C. Yazici, O. Canoz, M. Sipahioglu, A. Uzum, R. Ersoy, and E. Y. Sozmen Preventive effect of nebivolol on contrast-induced nephropathy in rats Nephrol. Dial. Transplant., March 1, 2008; 23(3): 853 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Kelly, B. Dwamena, P. Cronin, S. J. Bernstein, and R. C. Carlos Meta-analysis: Effectiveness of Drugs for Preventing Contrast-Induced Nephropathy Ann Intern Med, February 19, 2008; 148(4): 284 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. C. Wong and M. G. Irwin Contrast-induced nephropathy Br. J. Anaesth., October 1, 2007; 99(4): 474 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Solomon Contrast media nephropathy--how to diagnose and how to prevent? Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1812 - 1815. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Briguori, F. Airoldi, D. D'Andrea, E. Bonizzoni, N. Morici, A. Focaccio, I. Michev, M. Montorfano, M. Carlino, J. Cosgrave, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A Randomized Comparison of 3 Preventive Strategies Circulation, March 13, 2007; 115(10): 1211 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Djamali, M. Samaniego, B. Muth, R. Muehrer, R. M. Hofmann, J. Pirsch, A. Howard, G. Mourad, and B. N. Becker Medical Care of Kidney Transplant Recipients after the First Posttransplant Year Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 623 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pannu, N. Wiebe, M. Tonelli, and for the Alberta Kidney Disease Network Prophylaxis Strategies for Contrast-Induced Nephropathy JAMA, June 21, 2006; 295(23): 2765 - 2779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tepel, P. Aspelin, and N. Lameire Contrast-Induced Nephropathy: A Clinical and Evidence-Based Approach Circulation, April 11, 2006; 113(14): 1799 - 1806. [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Barrett and P. S. Parfrey Preventing Nephropathy Induced by Contrast Medium N. Engl. J. Med., January 26, 2006; 354(4): 379 - 386. [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted Evid. Based Med., August 1, 2005; 10(4): 127 - 128. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Goldenberg and S. Matetzky Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies Can. Med. Assoc. J., May 24, 2005; 172(11): 1461 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. O'Neill, S. R. Dixon, and C. L. Grines The year in interventional cardiology J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1117 - 1134. [Full Text] [PDF]
|
|